AVXL Overview

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.

Wall Street analysts forecast AVXL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVXL is20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Anavex Life Sciences Corp revenue for the last quarter amounts to -6.75M USD, decreased -48.75

Anavex Life Sciences Corp. EPS for the last quarter amounts to USD, decreased

Anavex Life Sciences Corp (AVXL) has 34 emplpoyees as of April 21 2026.

Today AVXL has the market capitalization of 338.25M USD.